Aurinia Pharmaceuticals Inc. (AUPH)
USD 8.21
(0.12%)
USD 8.21
(0.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 548.06 Million USD | 16.4% |
| 2022 | 470.86 Million USD | -13.34% |
| 2021 | 543.36 Million USD | 17.19% |
| 2020 | 463.66 Million USD | 41.93% |
| 2019 | 326.68 Million USD | 123.97% |
| 2018 | 145.86 Million USD | -23.17% |
| 2017 | 189.84 Million USD | 233.08% |
| 2016 | 56.99 Million USD | 69.8% |
| 2015 | 33.56 Million USD | -35.91% |
| 2014 | 52.37 Million USD | 126.33% |
| 2013 | 23.14 Million USD | 456.37% |
| 2012 | 4.15 Million USD | -70.96% |
| 2011 | 14.32 Million USD | 39.28% |
| 2010 | 10.28 Million USD | 7.7% |
| 2009 | 9.54 Million USD | -64.19% |
| 2008 | 26.65 Million USD | -37.52% |
| 2007 | 42.66 Million USD | 39.27% |
| 2006 | 30.63 Million USD | -43.63% |
| 2005 | 54.34 Million USD | -11.15% |
| 2004 | 61.17 Million USD | -17.82% |
| 2003 | 74.43 Million USD | 46.87% |
| 2002 | 50.67 Million USD | 36.74% |
| 2001 | 37.06 Million USD | 165.34% |
| 2000 | 13.96 Million USD | 237.19% |
| 1999 | 4.14 Million USD | 165.12% |
| 1998 | 1.56 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 516.63 Million USD | -5.73% |
| 2024 Q2 | 523.52 Million USD | 1.33% |
| 2023 Q3 | 555.01 Million USD | 1.11% |
| 2023 FY | 548.06 Million USD | 16.4% |
| 2023 Q4 | 548.06 Million USD | -1.25% |
| 2023 Q1 | 451.76 Million USD | -4.06% |
| 2023 Q2 | 548.9 Million USD | 21.5% |
| 2022 Q1 | 506.9 Million USD | -6.71% |
| 2022 Q2 | 482.14 Million USD | -4.88% |
| 2022 Q3 | 488.29 Million USD | 1.27% |
| 2022 Q4 | 470.86 Million USD | -3.57% |
| 2022 FY | 470.86 Million USD | -13.34% |
| 2021 Q3 | 360.06 Million USD | -6.78% |
| 2021 FY | 543.36 Million USD | 17.19% |
| 2021 Q1 | 417.07 Million USD | -10.05% |
| 2021 Q2 | 386.26 Million USD | -7.39% |
| 2021 Q4 | 543.36 Million USD | 50.91% |
| 2020 Q3 | 461.75 Million USD | 56.38% |
| 2020 Q2 | 295.27 Million USD | -6.25% |
| 2020 Q4 | 463.66 Million USD | 0.41% |
| 2020 FY | 463.66 Million USD | 41.93% |
| 2020 Q1 | 314.97 Million USD | -3.58% |
| 2019 Q3 | 150.84 Million USD | -0.26% |
| 2019 Q1 | 164.5 Million USD | 12.78% |
| 2019 Q4 | 326.68 Million USD | 116.57% |
| 2019 FY | 326.68 Million USD | 123.97% |
| 2019 Q2 | 151.23 Million USD | -8.06% |
| 2018 Q2 | 167.85 Million USD | -4.85% |
| 2018 FY | 145.86 Million USD | -23.17% |
| 2018 Q3 | 157.69 Million USD | -6.05% |
| 2018 Q4 | 145.86 Million USD | -7.5% |
| 2018 Q1 | 176.41 Million USD | -7.08% |
| 2017 Q1 | 219.69 Million USD | 285.45% |
| 2017 Q2 | 207.8 Million USD | -5.41% |
| 2017 Q4 | 189.84 Million USD | -5.0% |
| 2017 Q3 | 199.83 Million USD | -3.83% |
| 2017 FY | 189.84 Million USD | 233.08% |
| 2016 Q2 | 30.18 Million USD | 8.78% |
| 2016 FY | 56.99 Million USD | 69.8% |
| 2016 Q1 | 27.74 Million USD | -17.33% |
| 2016 Q3 | 33.25 Million USD | 10.15% |
| 2016 Q4 | 56.99 Million USD | 71.42% |
| 2015 Q3 | 38.94 Million USD | -12.26% |
| 2015 Q2 | 44.38 Million USD | -7.55% |
| 2015 Q1 | 48 Million USD | -8.34% |
| 2015 FY | 33.56 Million USD | -35.91% |
| 2015 Q4 | 33.56 Million USD | -13.8% |
| 2014 Q3 | 56.39 Million USD | -6.29% |
| 2014 FY | 52.37 Million USD | 126.33% |
| 2014 Q2 | 60.17 Million USD | -4.89% |
| 2014 Q1 | 63.27 Million USD | 173.42% |
| 2014 Q4 | 52.37 Million USD | -7.12% |
| 2013 Q2 | 3.87 Million USD | 6.3% |
| 2013 Q1 | 3.64 Million USD | -12.38% |
| 2013 FY | 23.14 Million USD | 456.37% |
| 2013 Q4 | 23.14 Million USD | -0.8% |
| 2013 Q3 | 23.32 Million USD | 502.19% |
| 2012 Q3 | 7.73 Million USD | -14.04% |
| 2012 Q2 | 9 Million USD | -7.55% |
| 2012 Q1 | 9.73 Million USD | -31.99% |
| 2012 FY | 4.15 Million USD | -70.96% |
| 2012 Q4 | 4.15 Million USD | -46.26% |
| 2011 Q3 | 20.12 Million USD | 4.08% |
| 2011 Q2 | 19.33 Million USD | 27.74% |
| 2011 Q1 | 15.13 Million USD | 47.21% |
| 2011 FY | 14.32 Million USD | 39.28% |
| 2011 Q4 | 14.32 Million USD | -28.84% |
| 2010 Q3 | 12.53 Million USD | 55.64% |
| 2010 Q1 | 9.62 Million USD | 0.78% |
| 2010 FY | 10.28 Million USD | 7.7% |
| 2010 Q4 | 10.28 Million USD | -17.97% |
| 2010 Q2 | 8.05 Million USD | -16.29% |
| 2009 Q4 | 9.54 Million USD | -11.68% |
| 2009 FY | 9.54 Million USD | -64.19% |
| 2009 Q3 | 10.81 Million USD | 1.62% |
| 2009 Q2 | 10.63 Million USD | -20.09% |
| 2009 Q1 | 13.31 Million USD | -50.06% |
| 2008 Q1 | 30.52 Million USD | -28.46% |
| 2008 FY | 26.65 Million USD | -37.52% |
| 2008 Q3 | 33.34 Million USD | -14.76% |
| 2008 Q4 | 26.65 Million USD | -20.05% |
| 2008 Q2 | 39.11 Million USD | 28.16% |
| 2007 Q2 | 53.82 Million USD | -4.97% |
| 2007 FY | 42.66 Million USD | 39.27% |
| 2007 Q4 | 42.66 Million USD | -11.07% |
| 2007 Q3 | 47.97 Million USD | -10.86% |
| 2007 Q1 | 56.63 Million USD | 84.87% |
| 2006 Q1 | 47.8 Million USD | -12.04% |
| 2006 Q4 | 30.63 Million USD | -21.29% |
| 2006 Q3 | 38.92 Million USD | -13.11% |
| 2006 FY | 30.63 Million USD | -43.63% |
| 2006 Q2 | 44.79 Million USD | -6.29% |
| 2005 Q3 | 60.54 Million USD | 30.95% |
| 2005 Q1 | 53.16 Million USD | -13.09% |
| 2005 FY | 54.34 Million USD | -11.15% |
| 2005 Q4 | 54.34 Million USD | -10.23% |
| 2005 Q2 | 46.23 Million USD | -13.03% |
| 2004 Q4 | 61.17 Million USD | -6.18% |
| 2004 Q3 | 65.2 Million USD | 1.51% |
| 2004 FY | 61.17 Million USD | -17.82% |
| 2004 Q2 | 64.23 Million USD | -8.94% |
| 2004 Q1 | 70.54 Million USD | -5.22% |
| 2003 Q1 | 49.7 Million USD | -1.91% |
| 2003 FY | 74.43 Million USD | 46.87% |
| 2003 Q3 | 75.99 Million USD | 14.16% |
| 2003 Q4 | 74.43 Million USD | -2.05% |
| 2003 Q2 | 66.56 Million USD | 33.91% |
| 2002 FY | 50.67 Million USD | 36.74% |
| 2002 Q3 | 53.04 Million USD | -1.5% |
| 2002 Q1 | 38.12 Million USD | 0.0% |
| 2002 Q2 | 53.85 Million USD | 41.28% |
| 2002 Q4 | 50.67 Million USD | -4.47% |
| 2001 Q2 | 11.13 Million USD | -8.89% |
| 2001 Q3 | 30.59 Million USD | 174.85% |
| 2001 Q1 | 12.21 Million USD | -12.53% |
| 2001 FY | 37.06 Million USD | 165.34% |
| 2000 Q2 | 12.54 Million USD | 160.09% |
| 2000 Q3 | 12.16 Million USD | -3.05% |
| 2000 Q1 | 4.82 Million USD | 16.45% |
| 2000 Q4 | 13.96 Million USD | 14.83% |
| 2000 FY | 13.96 Million USD | 237.19% |
| 1999 Q3 | 1.87 Million USD | -29.17% |
| 1999 Q2 | 2.64 Million USD | 2.31% |
| 1999 Q1 | 2.58 Million USD | 0.0% |
| 1999 Q4 | 4.14 Million USD | 121.11% |
| 1999 FY | 4.14 Million USD | 165.12% |
| 1998 FY | 1.56 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -231.516% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 15.594% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1626.723% |
| Autolus Therapeutics plc | 375.38 Million USD | -46.002% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -7735.261% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1388.045% |
| Shattuck Labs, Inc. | 159.56 Million USD | -243.475% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -190.817% |
| CervoMed Inc. | 9.97 Million USD | -5395.722% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 3.228% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1838.506% |
| Aptose Biosciences Inc. | 12.92 Million USD | -4141.131% |
| Precision BioSciences, Inc. | 159.78 Million USD | -243.008% |
| Dyadic International, Inc. | 8.21 Million USD | -6568.041% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -101.383% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -3068.904% |
| Nektar Therapeutics | 398.03 Million USD | -37.693% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -167.151% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -461.05% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -54.304% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -652.574% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 17.103% |
| GRI Bio, Inc. | 2.95 Million USD | -18440.663% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -5067.848% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -221.416% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -17156.36% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -48308.572% |
| IGM Biosciences, Inc. | 423.41 Million USD | -29.44% |
| INmune Bio, Inc. | 57 Million USD | -861.495% |
| Opthea Limited | 188.79 Million USD | -190.301% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -628.554% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -168.177% |
| Verastem, Inc. | 149.71 Million USD | -266.063% |
| Abeona Therapeutics Inc. | 64 Million USD | -756.32% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -7.011% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -254.831% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 34.211% |
| NextCure, Inc. | 129.41 Million USD | -323.482% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3678.006% |
| Organovo Holdings, Inc. | 6.34 Million USD | -8532.257% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -12620.128% |
| Arvinas, Inc. | 1.3 Billion USD | 57.99% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -280.528% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -628.147% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -846.305% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -50.994% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -27.634% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -225.89% |
| Senti Biosciences, Inc. | 119.48 Million USD | -358.691% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -4245.656% |
| Apollomics, Inc. | 55.38 Million USD | -889.514% |
| PureTech Health plc | 693.97 Million USD | 21.025% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1392.178% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -155.5% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 4.811% |
| Synaptogenix, Inc. | 31.11 Million USD | -1661.483% |
| ChromaDex Corporation | 54.96 Million USD | -897.129% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 62.454% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -7361.54% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -126.75% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -50.344% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 30.513% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -6769.121% |
| Gritstone bio, Inc. | 177.76 Million USD | -208.3% |
| Mesoblast Limited | 669.15 Million USD | 18.096% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -5592.172% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -60.817% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -8.266% |
| MediWound Ltd. | 66.45 Million USD | -724.662% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -643.619% |
| Fortress Biotech, Inc. | 167.52 Million USD | -227.15% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -619.128% |
| Achilles Therapeutics plc | 161.45 Million USD | -239.45% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -52.834% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -10090.814% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -469.403% |
| Zai Lab Limited | 1.03 Billion USD | 47.113% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -4630.381% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 26.928% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 15.48% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -105.865% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -4535.643% |
| FibroGen, Inc. | 423.52 Million USD | -29.404% |
| Celcuity Inc. | 191.21 Million USD | -186.614% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -15500.968% |
| ContextLogic Inc. | 423 Million USD | -29.565% |
| GH Research PLC | 226.3 Million USD | -142.184% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -239.7% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -6124.441% |
| ImmuCell Corporation | 43.8 Million USD | -1151.052% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -5.915% |
| Amarin Corporation plc | 831.68 Million USD | 34.102% |
| TG Therapeutics, Inc. | 329.58 Million USD | -66.288% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2106.191% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -474.609% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -91.686% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -328.612% |
| Aptorum Group Limited | 20.64 Million USD | -2555.327% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 63.242% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -6.016% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2374.194% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 28.41% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -10501.425% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -216.198% |
| Ardelyx, Inc. | 297.57 Million USD | -84.174% |
| Ainos, Inc. | 31.84 Million USD | -1621.203% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -284.335% |
| Prothena Corporation plc | 696.38 Million USD | 21.299% |
| HilleVax, Inc. | 344.43 Million USD | -59.12% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -93.925% |
| Celularity Inc. | 143.88 Million USD | -280.892% |
| Rallybio Corporation | 115.62 Million USD | -374.02% |
| Cue Biopharma, Inc. | 61.53 Million USD | -790.723% |
| Omeros Corporation | 378.26 Million USD | -44.887% |
| Humacyte, Inc. | 128.22 Million USD | -327.429% |
| Immunocore Holdings plc | 597 Million USD | 8.197% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1653.293% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 47.766% |
| IO Biotech, Inc. | 150.71 Million USD | -263.634% |
| MEI Pharma, Inc. | 41.37 Million USD | -1224.621% |
| GT Biopharma, Inc. | 14.1 Million USD | -3784.485% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -116.07% |
| Summit Therapeutics Inc. | 202.94 Million USD | -170.049% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -6532.724% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -220.677% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -76.206% |
| Pulmatrix, Inc. | 33.95 Million USD | -1513.941% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1918.942% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -272.178% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -289.088% |
| Acelyrin, Inc. | 742.69 Million USD | 26.206% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 57.873% |
| Cytokinetics, Incorporated | 824.31 Million USD | 33.513% |
| Vor Biopharma Inc. | 209.82 Million USD | -161.196% |
| Evogene Ltd. | 51.1 Million USD | -972.507% |
| Replimune Group, Inc. | 487.72 Million USD | -12.372% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -899.511% |
| PDS Biotechnology Corporation | 59.39 Million USD | -822.817% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -5656.786% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -0.308% |
| AEON Biopharma, Inc. | 6.84 Million USD | -7906.749% |
| BioLineRx Ltd. | 63.92 Million USD | -757.352% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1843.482% |
| Atai Life Sciences N.V. | 293.47 Million USD | -86.747% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -330.129% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -343.226% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 2.485% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -466.654% |
| MediciNova, Inc. | 66.26 Million USD | -727.014% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -523.166% |
| MiMedx Group, Inc. | 239.04 Million USD | -129.27% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -12181.873% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 6.83% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 71.203% |
| Mereo BioPharma Group plc | 66.49 Million USD | -724.166% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 10.576% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -7392.303% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -231.994% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -9233.066% |
| Allakos Inc. | 243.61 Million USD | -124.975% |
| scPharmaceuticals Inc. | 94.47 Million USD | -480.089% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -112.679% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 11.819% |
| NLS Pharmaceutics AG | 1.84 Million USD | -29578.86% |
| Precigen, Inc. | 151.04 Million USD | -262.852% |
| XOMA Corporation | 234.3 Million USD | -133.914% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -147.728% |
| Incyte Corporation | 6.78 Billion USD | 91.919% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -86675.24% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -335.509% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -256.109% |
| Seer, Inc. | 436.26 Million USD | -25.625% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2796.171% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 75.418% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 5.551% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -396.123% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -3515.767% |
| Akari Therapeutics, Plc | 4.35 Million USD | -12484.661% |
| Novavax, Inc. | 1.85 Billion USD | 70.46% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -17671.222% |
| UroGen Pharma Ltd. | 178.31 Million USD | -207.363% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -16.427% |
| Entera Bio Ltd. | 11.76 Million USD | -4558.411% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -902.051% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -140.018% |
| Chimerix, Inc. | 212.77 Million USD | -157.579% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -410.129% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -32.433% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1596.734% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.19% |
| AnaptysBio, Inc. | 452.38 Million USD | -21.148% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2319.681% |
| Portage Biotech Inc. | 7.77 Million USD | -6945.404% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -97.896% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -117.354% |
| OKYO Pharma Limited | 1.54 Million USD | -35459.255% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -26855.0% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -6333.219% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -9371.156% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 63.17% |
| Genprex, Inc. | 10.67 Million USD | -5036.191% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -10.453% |
| NLS Pharmaceutics AG | 1.84 Million USD | -29578.86% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -13057.358% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2475.211% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -6677.912% |
| Bicycle Therapeutics plc | 595.34 Million USD | 7.942% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 73.759% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -53.111% |
| Erasca, Inc. | 395.29 Million USD | -38.646% |
| bluebird bio, Inc. | 619.16 Million USD | 11.483% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1316.913% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 91.989% |
| DBV Technologies S.A. | 182.98 Million USD | -199.51% |
| Fortress Biotech, Inc. | 167.52 Million USD | -227.15% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 12.806% |
| CorMedix Inc. | 82.05 Million USD | -567.88% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 30.529% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -636.9% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -475.623% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -427.256% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -17.704% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -79.663% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -74.856% |
| Onconetix, Inc. | 88.82 Million USD | -517.038% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -915.908% |
| Prime Medicine, Inc. | 193.85 Million USD | -182.723% |
| Adagene Inc. | 115.72 Million USD | -373.574% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -78.004% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1109.41% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 63.154% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 27.186% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -56.018% |
| SciSparc Ltd. | 11.18 Million USD | -4801.288% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4387.673% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -863.192% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -115.208% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -200.489% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3116.83% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -60.55% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -3099.915% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 85.69% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2583.421% |
| 2seventy bio, Inc. | 565.42 Million USD | 3.071% |
| ADMA Biologics, Inc. | 329.18 Million USD | -66.492% |
| Clene Inc. | 52.34 Million USD | -947.099% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -833.12% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -321.93% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 16.16% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -428.96% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -320.338% |
| Absci Corporation | 234.48 Million USD | -133.735% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.343% |
| Surrozen, Inc. | 46.08 Million USD | -1089.371% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -24.286% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -44.073% |
| Cingulate Inc. | 3.49 Million USD | -15597.323% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -3195.821% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -4590.454% |
| Jaguar Health, Inc. | 50.76 Million USD | -979.649% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -104.107% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 26.823% |
| Kronos Bio, Inc. | 213.27 Million USD | -156.97% |
| Innoviva, Inc. | 1.24 Billion USD | 55.926% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -243.002% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -16.81% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2378.317% |
| Soligenix, Inc. | 9.79 Million USD | -5493.996% |
| AlloVir, Inc. | 190.79 Million USD | -187.25% |
| Century Therapeutics, Inc. | 360.69 Million USD | -51.948% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -115.191% |
| Kura Oncology, Inc. | 448.93 Million USD | -22.08% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -394.144% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -117.8% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1015.489% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -8459.457% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -146.313% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -552.911% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1998.499% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -7862.32% |
| HCW Biologics Inc. | 28.51 Million USD | -1822.103% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -45.587% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -231.147% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 12.951% |
| Lantern Pharma Inc. | 43.64 Million USD | -1155.652% |
| Histogen Inc. | 19.07 Million USD | -2773.497% |
| Surrozen, Inc. | 46.08 Million USD | -1089.371% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -335.336% |
| Kodiak Sciences Inc. | 479.37 Million USD | -14.329% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -4.087% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2928.904% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -216.781% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2510.689% |
| Moderna, Inc. | 18.42 Billion USD | 97.026% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 81.671% |
| Turnstone Biologics Corp. | 112.81 Million USD | -385.806% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2650.603% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -4398.211% |
| Exelixis, Inc. | 2.94 Billion USD | 81.373% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -80.429% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -99.332% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -7486.683% |
| Alkermes plc | 2.13 Billion USD | 74.344% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -474.609% |
| Arcellx, Inc. | 825.13 Million USD | 33.579% |
| ESSA Pharma Inc. | 149.12 Million USD | -267.526% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2968.266% |
| Avid Bioservices, Inc. | 336.55 Million USD | -62.844% |
| Insmed Incorporated | 1.32 Billion USD | 58.787% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -571.34% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -18.558% |
| Moolec Science SA | 24.05 Million USD | -2178.722% |
| RenovoRx, Inc. | 1.46 Million USD | -37284.857% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -76.723% |
| Geron Corporation | 394.07 Million USD | -39.075% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -438.848% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -571.669% |
| Royalty Pharma plc | 16.38 Billion USD | 96.654% |
| OmniAb, Inc. | 401.98 Million USD | -36.339% |
| Alector, Inc. | 621.82 Million USD | 11.863% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 7.884% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -142.441% |
| Humacyte, Inc. | 128.22 Million USD | -327.429% |
| Structure Therapeutics Inc. | 482.01 Million USD | -13.702% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -14.549% |
| 89bio, Inc. | 596.26 Million USD | 8.085% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -29524.973% |
| Aura Biosciences, Inc. | 255.07 Million USD | -114.863% |
| Immunic, Inc. | 54.29 Million USD | -909.341% |
| Veracyte, Inc. | 1.13 Billion USD | 51.832% |
| Genelux Corporation | 27.89 Million USD | -1864.873% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -513.024% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -11470.777% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -9994.193% |
| Immunovant, Inc. | 666.71 Million USD | 17.796% |
| Vericel Corporation | 353.65 Million USD | -54.97% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 87.422% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -132.818% |
| XBiotech Inc. | 227.24 Million USD | -141.179% |
| Agenus Inc. | 313.91 Million USD | -74.59% |
| Acasti Pharma Inc. | 73.3 Million USD | -647.697% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3896.989% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -11939.283% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1998.499% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -43.472% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -50.219% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2305.786% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2845.092% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -962.074% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1110.197% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -64.709% |
| United Therapeutics Corporation | 7.16 Billion USD | 92.353% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -5014.814% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -9233.066% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -12620.128% |
| Silo Pharma, Inc. | 7.74 Million USD | -6975.291% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -11380.7% |
| Pharming Group N.V. | 462.85 Million USD | -18.409% |
| XOMA Corporation | 234.3 Million USD | -133.914% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2796.171% |
| Bionomics Limited | 27.64 Million USD | -1882.206% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -410.357% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -215.475% |
| uniQure N.V. | 831.68 Million USD | 34.103% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -799.554% |
| Cassava Sciences, Inc. | 151.66 Million USD | -261.368% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -6941.086% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1591.236% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -100.107% |
| Pluri Inc. | 39.52 Million USD | -1286.551% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -13355.602% |
| MeiraGTx Holdings plc | 458.16 Million USD | -19.62% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -699.74% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2937.203% |
| CalciMedica, Inc. | 12.18 Million USD | -4397.842% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 3.049% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 29.544% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -8220.961% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -410.357% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -320.974% |
| Nutriband Inc. | 7.51 Million USD | -7190.818% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -594.154% |
| Compugen Ltd. | 121.33 Million USD | -351.697% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 92.412% |
| ProKidney Corp. | 420.55 Million USD | -30.32% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -12576.734% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -10460.128% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -36.142% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -235.968% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -218.036% |
| Benitec Biopharma Inc. | 52.21 Million USD | -949.726% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5803.793% |
| Biomea Fusion, Inc. | 199.92 Million USD | -174.131% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -12.98% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -61.246% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -4.131% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2756.721% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -60.318% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -97.363% |
| Imunon, Inc. | 21.91 Million USD | -2400.503% |
| BioAtla, Inc. | 119.65 Million USD | -358.024% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 14.743% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -471.285% |
| Zura Bio Limited | 100.84 Million USD | -443.48% |
| aTyr Pharma, Inc. | 122.06 Million USD | -348.985% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 14.438% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -11.753% |
| Galecto, Inc. | 38.22 Million USD | -1333.704% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3116.83% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 68.38% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -138.881% |
| PolyPid Ltd. | 15.37 Million USD | -3465.327% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -359.452% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1306.008% |
| Xencor, Inc. | 952.69 Million USD | 42.472% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -6690.434% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -17671.222% |
| Instil Bio, Inc. | 325.63 Million USD | -68.308% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -12181.873% |
| OncoCyte Corporation | 74.89 Million USD | -631.803% |
| Elevation Oncology, Inc. | 89.09 Million USD | -515.171% |
| Purple Biotech Ltd. | 44.3 Million USD | -1137.104% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1505.995% |
| MacroGenics, Inc. | 306.82 Million USD | -78.627% |
| Verona Pharma plc | 308.12 Million USD | -77.871% |
| Tharimmune, Inc. | 10.94 Million USD | -4906.782% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -36.536% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -530.253% |
| Aditxt, Inc. | 44.57 Million USD | -1129.436% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -22491.179% |
| Savara Inc. | 177.56 Million USD | -208.656% |
| Curis, Inc. | 77.28 Million USD | -609.172% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -757.032% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2729.291% |
| BeiGene, Ltd. | 5.8 Billion USD | 90.559% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -12576.734% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2908.52% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -4712.627% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -296.385% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -367.53% |
| Adicet Bio, Inc. | 207.29 Million USD | -164.387% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -12204.417% |
| Quantum-Si incorporated | 298.25 Million USD | -83.759% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -7009.265% |
| Generation Bio Co. | 374.75 Million USD | -46.244% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -245.634% |
| Invivyd, Inc. | 229.18 Million USD | -139.139% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 35.062% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -4403.644% |
| Moolec Science SA | 24.05 Million USD | -2178.722% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1511.094% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -981.054% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -461.815% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -125.956% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 72.039% |
| Evaxion Biotech A/S | 12.88 Million USD | -4152.294% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -117.433% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -142.659% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -734.316% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -335.343% |
| Clearmind Medicine Inc. | 4.32 Million USD | -12573.744% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -313.872% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -16.138% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -6302.137% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -48.732% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -48.115% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 13.739% |
| ImmunityBio, Inc. | 504.45 Million USD | -8.645% |
| Korro Bio, Inc. | 221.66 Million USD | -147.25% |
| Kineta, Inc. | 10.28 Million USD | -5230.824% |
| BioVie Inc. | 25.2 Million USD | -2074.129% |
| Codexis, Inc. | 136.56 Million USD | -301.331% |
| Celularity Inc. | 143.88 Million USD | -280.892% |
| Virax Biolabs Group Limited | 5.48 Million USD | -9893.893% |
| Cibus, Inc. | 544.41 Million USD | -0.671% |
| Annexon, Inc. | 297.67 Million USD | -84.115% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -298.68% |
| Eyenovia, Inc. | 28.77 Million USD | -1804.357% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -137.742% |
| NeurAxis, Inc. | 509.49 Thousand USD | -107469.019% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1682.315% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -249.362% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -4456.811% |
| Notable Labs, Ltd. | 19.54 Million USD | -2704.677% |
| IN8bio, Inc. | 33.7 Million USD | -1525.863% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -911.931% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -212.204% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1248.644% |
| Liquidia Corporation | 120.43 Million USD | -355.084% |
| Mustang Bio, Inc. | 17.74 Million USD | -2989.065% |
| Quantum-Si incorporated | 298.25 Million USD | -83.759% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -279.542% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -530.253% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -135.03% |
| 180 Life Sciences Corp. | 5.25 Million USD | -10320.468% |
| Vaxcyte, Inc. | 1.4 Billion USD | 61.073% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 43.194% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -12204.417% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1476.114% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -678.19% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -6302.137% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -203.314% |
| PepGen Inc. | 143.05 Million USD | -283.121% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1334.079% |
| Solid Biosciences Inc. | 164.93 Million USD | -232.282% |
| Palisade Bio, Inc. | 14.05 Million USD | -3800.242% |
| Nutriband Inc. | 7.51 Million USD | -7190.818% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -7486.683% |
| Immuneering Corporation | 102.58 Million USD | -434.254% |
| Belite Bio, Inc | 94.64 Million USD | -479.09% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -174.992% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5803.793% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -160.616% |
| Altimmune, Inc. | 210.64 Million USD | -160.189% |
| Peak Bio, Inc. | 2.59 Million USD | -21008.413% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -15500.968% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -4536.342% |
| Neurogene Inc. | 222.57 Million USD | -146.239% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 15.242% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -8736.859% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -20.975% |
| Sesen Bio, Inc. | 189.17 Million USD | -189.713% |
| argenx SE | 4.54 Billion USD | 87.935% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1476.114% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -205.489% |
| Immunome, Inc. | 148.54 Million USD | -268.966% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -8858.95% |
| Design Therapeutics, Inc. | 289.64 Million USD | -89.22% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -10015.578% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -101.592% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 29.767% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -105.271% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -216.901% |
| Athira Pharma, Inc. | 160.24 Million USD | -242.015% |
| XOMA Corporation | 234.3 Million USD | -133.914% |
| Merus N.V. | 458.49 Million USD | -19.535% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -204.134% |
| Rezolute, Inc. | 132.73 Million USD | -312.893% |
| Clene Inc. | 52.34 Million USD | -947.099% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3572.383% |
| BeyondSpring Inc. | 24.8 Million USD | -2109.215% |
| Synlogic, Inc. | 75.55 Million USD | -625.43% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -4520.317% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -5752.862% |
| Peak Bio, Inc. | 2.59 Million USD | -21008.413% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -213.477% |
| Krystal Biotech, Inc. | 818.35 Million USD | 33.029% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -127.943% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 24.487% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -15221.089% |
| MannKind Corporation | 475.19 Million USD | -15.333% |
| Ikena Oncology, Inc. | 192.09 Million USD | -185.312% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3997.966% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -370.282% |
| Gossamer Bio, Inc. | 311.91 Million USD | -75.708% |
| CohBar, Inc. | 16.36 Million USD | -3248.852% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1458.633% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -7392.303% |
| Legend Biotech Corporation | 1.84 Billion USD | 70.353% |
| Mural Oncology plc | 301.74 Million USD | -81.631% |
| Disc Medicine, Inc. | 367.99 Million USD | -48.932% |
| Champions Oncology, Inc. | 26.13 Million USD | -1997.283% |
| REGENXBIO Inc. | 573.97 Million USD | 4.514% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -20137.991% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -254.995% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -4438.598% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -61.178% |
| Vaxart, Inc. | 91.83 Million USD | -496.822% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -814.902% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -269.496% |
| Cellectis S.A. | 334.27 Million USD | -63.958% |
| Longeveron Inc. | 12.17 Million USD | -4400.427% |
| Repare Therapeutics Inc. | 253.9 Million USD | -115.857% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 83.212% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -172.875% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 73.759% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -33626.892% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -97.35% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -236.032% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -295.017% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2047.41% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.589% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 52.504% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4387.673% |
| Veru Inc. | 50.59 Million USD | -983.214% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1103.13% |
| Cingulate Inc. | 3.49 Million USD | -15597.323% |
| Passage Bio, Inc. | 150.54 Million USD | -264.052% |
| Context Therapeutics Inc. | 16.06 Million USD | -3312.009% |
| Exicure, Inc. | 11.58 Million USD | -4632.832% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -45.743% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -239.059% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -3036.802% |
| Nuvalent, Inc. | 732.38 Million USD | 25.167% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -3567.419% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -511.991% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3762.039% |
| OmniAb, Inc. | 401.98 Million USD | -36.339% |
| Anew Medical, Inc. | 19.45 Million USD | -2716.937% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1950.627% |
| Lipocine Inc. | 23 Million USD | -2282.767% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -292.013% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -79.36% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -552.911% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -350.931% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -6806.894% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 37.881% |
| Ocugen, Inc. | 64.54 Million USD | -749.09% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -340.066% |
| Q32 Bio Inc. | 306.11 Million USD | -79.036% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -12924.287% |
| Alumis Inc. Common Stock | 89.61 Million USD | -511.594% |
| Equillium, Inc. | 50.53 Million USD | -984.627% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -628.854% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1227.878% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -32122.773% |
| Dominari Holdings Inc. | 57.55 Million USD | -852.191% |
| Edesa Biotech, Inc. | 8.89 Million USD | -6064.624% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4874.242% |
| Bio-Techne Corporation | 2.81 Billion USD | 80.518% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 41.516% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 32.459% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -97.382% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1214.234% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 17.904% |
| Nkarta, Inc. | 378.88 Million USD | -44.651% |
| BioCardia, Inc. | 2.98 Million USD | -18248.242% |
| Iterum Therapeutics plc | 26.25 Million USD | -1987.14% |